Cargando…
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
BACKGROUND: Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet‐derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR is a two‐part, single‐arm, dose escalation and expansion study designed to evalu...
Autores principales: | George, Suzanne, Jones, Robin L., Bauer, Sebastian, Kang, Yoon‐Koo, Schöffski, Patrick, Eskens, Ferry, Mir, Olivier, Cassier, Phillipe A., Serrano, Cesar, Tap, William D., Trent, Jonathan, Rutkowski, Piotr, Patel, Shreyaskumar, Chawla, Sant P., Meiri, Eval, Gordon, Michael, Zhou, Teresa, Roche, Maria, Heinrich, Micahel C., von Mehren, Margaret |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018324/ https://www.ncbi.nlm.nih.gov/pubmed/33453089 http://dx.doi.org/10.1002/onco.13674 |
Ejemplares similares
-
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
por: Jones, Robin L., et al.
Publicado: (2021) -
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
por: Joseph, Cissimol P., et al.
Publicado: (2021) -
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
por: Kang, Yoon-Koo, et al.
Publicado: (2021) -
Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021) -
Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment
por: Ye, Shuai, et al.
Publicado: (2021)